Pharmacokinetics of biotech drugs: Peptides, proteins and monoclonal antibodies

Current Drug Metabolism

Volumn 10, Issue 7, 2009, Pages 661-691

  Lin, Jiunn H ^a  

^a NONE   (United States)

Author keywords

Allometric scaling; Asialoglycoprotein receptor; Clathrin mediated and caveolae mediated endocytosis; Endopeptidase and exopeptidase; Enhanced permeability and retention effect; Lymphatic absorption; Lysosomal degradation; Mannose receptor; Nanoparticulate delivery systems; Neonatal Fc receptor (FcRn); Receptor mediated endocytosis; Ubinquitin protesome system

Indexed keywords

ALBUMIN; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CALCITONIN; CAPTOPRIL; CHROMIUM 51; CLATHRIN; CRM 107; DOXORUBICIN; DOXORUBICIN PLUS TRANSFERRIN RECEPTOR; ENZYME INHIBITOR; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GLUCAGON LIKE PEPTIDE 1; GONADORELIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; INSULIN; LIPOSOME; MACROGOL; METHOTREXATE; MITOXANTRONE; NANOPARTICLE; NANOSPHERE; PECTINE LIPOSOME NANOCOMPLEX; PROTEINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 10; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONULA OCCLUDEN TPXIN;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BIOTECHNOLOGY; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG EXTRAVASATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SELECTIVITY; DRUG TARGETING; ENDOCYTOSIS; ENZYMATIC DEGRADATION; HUMAN; INTESTINE ABSORPTION; LIPOSOMAL DELIVERY; LOW DRUG DOSE; LYMPHATIC SYSTEM; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MOLECULAR SIZE; NONHUMAN; PHARMACOKINETICS; PINOCYTOSIS; PROTEIN DEPLETION; PROTEIN METABOLISM; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSCYTOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; DNA, RECOMBINANT; DRUG DESIGN; HUMANS; PEPTIDES; PROTEINS;

EID: 72949106918     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009789895499     Document Type: Review

References (206)

1. Reichert, J.M. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol., 2008, 9(6), 423-430.
2. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 2004, 3(8), 711-715.
3. Tang, L.; Persky, A.M.; Hochhaus, G.; Meibohm, B. Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci., 2004, 93(9), 2184-2204.
4. Lobo, E.D.; Hansen, R.J.; Balthasar, J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci., 2004, 93(11), 2645-2668.
5. Woodley, J.F. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst., 1994, 11(2-3), 61-95.
6. Woodley, J. F. Mucosal peptide hydrolase and brush-border marker enzyme activities in three regions of the small intestine of rats with experimental uraemia. Proc. Int. Symp. Control Release Bioact. Mater., 1991, 18(3), 337-342.
7. Olsen, J.V.; Ong, S-E.; Mann, M. Trypsin cleaves exclusively C-terminal to arginine and lysine residues. Mol. Cell. Proteomics, 2004, 3(6), 608-614.
8. Kageyama, T. Roles of Tyr13 and Phe219 in the unique substrate specificity of pepsin B. Biochemistry, 2006, 45(48), 14415-14426.
9. Guan, D.; Yoshioka, M.; Erickson, R.H.; Heizer, W.; Kim, Y.S. Protein digestion in human and rat small intestine: role of new neutral endopeptidases. Am. J. Physiol., 1988, 255(2 part 1), G212-G220.
10. Pade, V.; Stavchansky, S. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm. Res., 1997, 14(9), 1210-1215.
11. van Itallie, C.M.; Anderson, J.M. The molecular physiology of tight junction pores. Physiology, 2004, 19(4), 331-338.
12. Watson, C.J.; Rowland, M.; Warhurst, G. Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers. Am. J. Physiol. Cell Physiol., 2001, 281(2), c388-c397.
13. He, Y-L.; Murby S.; Warhurst, G.; Gifford, L.; Walker, D.; Ayrton, J.; Eastmond, R.; Rowland, M. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J. Pharm. Sci., 1998, 87(5), 626-633.
14. Sinko, P.J.; Lee, Y-H.; Makhey, V.; Leesman, G.D.; Sutyak, J.P.; Yu, H.; Perry, B.; Smith, C.T.; Hu, P.; Wagner, E.J.; Falzone, L.M.; McWhorter, L.T.; Gilligan, J.P.; Stern, W. Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT). Pharm. Res., 1999, 16(4), 527-533.
15. Antonin K.H.; Saano, V.; Bieck, P.; Hastewell, J.; Fox, R.; Lowe, P.; Mackay, M. Colonic absorption of human calcitonin in man. Clin. Sci., 1992, 83(5), 627-631.
16. Leone-Bay, A.; Ho, K.K; Agarwal, R.; Baughman, R.A,; Chaudhary, K.; DeMorin, F.; Genoble, L.; McInnes, C.; Lercara, C.; Milstein, S.; O'Toole, D.: Sarubbi, D.; Variano, B.; Paton, D.R. J. 4-[4-[(2-Hydroxybenzoyl)amino] phenyl]butyric acid as a novel oral delivery agent for recombinant human growth hormone. Med. Chem., 1996, 39(13), 2571-2578.
17. Eyles, J.E.; Alpar, H.O.; Conway, B.R.; Kewick, M. J. Pharm. Pharmacol., 1997, 49(7), 669-674.
18. Yamamoto, A.; Taniguchi, T.; Rikyuu, K.; Tsuji, T.; Fujita, T.; Murakami, M.; Muranishi, S. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res., 1994, 11(10), 1496-1500.
19. Liu, H.; Tang, R.; Pan, W-S.; Zhang, Y.; Liu, H. Potential utility of various protease inhibitors for improving the intestinal absorption of insulin in rats. J. Pharm. Pharmcol., 2003, 55(11), 1523-1529
20. Tozaki, H.; Odoriba, T.; Iseki, T.; Taniguchi, T.; Fujita, T.; Murakami, M.; Muranishi, S.; Yamamoto, A. Use of protease inhibitors to improve calcitonin absorption from the small and large intestine in rats. J. Pharm. Pharmcol., 1998, 50(8), 913-920.
21. Agarwal, V.; Nazzal, S.; Reddy, I.K.; Khan, M.A. Transport studies of insulin across rat jejunum in the presence of chicken and duck ovomucoids. J. Pharm. Pharmacol., 2001, 53(8), 1131-1138.
22. Fasano, A.; Baudry, B.; Pumplin, D.W.; Wasserman, S.S.; Tall, B.D.; Ketley, J.M.; Kaper, J.B. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc. Natl. Acad. Sci. USA, 1991, 88(12), 5242-5246.
23. Fasano, A.; Uzzau, S. Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J. Clin. Invest., 1997, 99(6), 1158-1164.
24. Khafagy, EL-S.; Morishita, M.; Onuki, Y.; Takayama, K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv. Drug Deliv. Rev., 2007, 59(15), 1521-1546.
25. Damge, C.; Vranckx, H.; Balschmidt, P.; Couvreur, P. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci., 1997, 86(12), 1403-1409.
26. Lowe, P.J.; Temple, C.S. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats. J. Pharm. Pharmacol., 1994, 46(7), 547-552.
27. Damge, C.; Reis, C.P.; Maincent, P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin. Drug Deliv., 2008, 5(1), 45-68.
28. Pinto-Alphandary, H.; Aboubakar, M.; Jaillard, D.; Couvreur, P.; Vauthier, C. Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats. Pharm. Res., 2003, 20(7), 1071-1084.
29. Shakweh, M.; Besnard, M.; Nicolas, V.; Fatal, E. Poly (lactide-coglycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur. J. Pharm. Biopharm., 2005, 61(1-2), 1-13.
30. Cui, F.; Shi, K.; Zhang, L.; Tao, A.; Kawashima, Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J. Control. Release, 2006, 114(2), 242-250.
31. Bernkop-Schnurch, A. Mucoadhesive polymers: strategies, achievements and future challenges. Adv. Drug Deliv. Rev., 2005, 57(11), 1553-1555.
32. Smart, J.D. The basics and underlying mechanisms of mucoadhesion. Adv. Drug Deliv. Rev., 2005, 57(11), 1556-1568.
33. Calceti, P.; Salmaso, S.; Walker, G.; Bernkop-Schnurch, A. Development and in vivo evaluation of an oral insulin-PEG delivery system. Eur. J. Pharm. Sci., 2004, 22(4), 315-323.
34. Thirawong, N.; Thongborisute, J.; Takeuchi, H.; Sriamornsak, P. J. Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. Control. Release, 2008, 125(3), 236-245.
35. Bill, A. Plasma protein dynamics: albumin and IgG capillary permeability, extravascular movement and regional blood flow in unanesthetized rabbits. Acta Physiol. Scand., 1977, 101(1), 28-42.
36. Yang, V.V.; O'Morchoe, P.J.; O'Morchoe, C.C. Transport of protein across lymphatic endothelium in the rat kidney. Microvasc. Res., 1981, 21(1), 75-91.
37. Casley-Smith, J.R. The fine structure and functioning of tissue channels and lymphatics. Lymphology, 1980, 13(2), 177-183.
38. Swartz, M.A. The physiology of the lymphatic system. Adv. Drug Deliv. Rev., 2001, 50(1-2), 3-20.
39. Knott, E.M.; Tune, J.D.; Stoll, S.T.; Downey, H.F. Increased lymphatic flow in the thoracic duct during manipulative intervention. J. Am. Osteopathol. Assoc., 2005, 105(10), 447-456.
40. Supersaxo, A.; Hein, W.R.; Steffen, H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res., 1990, 7(2), 167-169.
41. Charman, S.A.; McLennan, D.N.; Edwards, G.A.; Porter, C.J.H. Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model. Pharm. Res., 2001, 18(11), 1620-1626.
42. Charman, S.A.; Segrave, A.M.; Edwards, G.A.; Porter, C.J.H. Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. J. Pharm. Sci., 2000, 89(2), 168-177.
43. McLennan, D.N.; Porter, C.J.H.; Edwards, G.A.; Heatherington, A.C.; Martin, S.W.; Charman, S.A. The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep. Pharm. Res., 2006, 23(9), 2060-2066.
44. Porter, C.J.; Charman, S. A. Lymphatic transport of proteins after subcutaneous administration. J. Pharm. Sci., 2000, 89(3), 297-310.
45. Beshyah, S.A.; Anyaoku, V.; Niththyananthan, R.; Sharp, P.; Johnston, D.G. The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh. Clin. Endocrinol., 1991, 35(5), 409-412.
46. Macdougall, I.C.; Jones, J.M.; Robinson, M.I.; Miles, J.B.; Coles, G.A.; Williams, J.D. Subcutaneous erythropoietin therapy: comparison of three different sites of injection. Contrib. Nephrol., 1991, 88(2), 152-156.
47. Jensen, J.D.; Jensen, L.W.; Madsen, J.K. The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur. J. Clin. Pharmacol., 1994, 46(4),333-337.
48. Fishbane, S.; Pannier, A.; Liogier, X.; Jordan, P.; Dougherty, F.C.; Reigner, B. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J. Clin. Pharmacol., 2007, 47(11), 1390-1397.
49. Kota, J.; Machavaram, K.; McLennan, D.N.; Edwards, G.A.; Porter, C.J.H.; Charman, S.A. Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. Drug Metab. Dispos., 2007, 35(12), 2211-2217.
50. Ikomi, F.; Hunt, J.; Hanna, G.; Schmid-Schonbein, G.W. Interstitial fluid, plasma protein, colloid, and leukocyte uptake into initial lymphatics. J. Appl. Physiol. 1996, 81(5), 2060-2067.
51. Wiig, H.; Gyenge, C.; Inversen, P.O.; Gullberg, D.; Tenstad, O. The role of the extracellular matrix in tissue distribution of macromolecules in normal and pathological tissues: potential therapeutic consequences. Microcirculation, 2008, 15(4), 283-296.
52. Kagan, L.; Gershkovich, P.; Mendelman, A.; Amsili, S.; Ezov, N.; Hoffman, A. The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur. J. Pharm. Biopharm., 2007, 67(3), 759-765.
53. Kojima, K.; Takahashi, T.; Nakanishi, Y. Lymphatic transport of recombinant human tumor necrosis factor in rats. J. Pharmacobiodyn., 1988, 11(10), 700-706.
54. Xie, D.D.; Hale, V. Lymphatic absorption of proteins in rats. Pharm. Res., 1996, 13, S396.
55. Bocci, V.; Muscettola, M.; Grasso, G.; Magyar, Z.; Naldini, A.; Szabo, G. The lymphatic route. 1) Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasma. Experientia., 1986, 42(4), 432-433.
56. Ono, N.; Mizuno, R.; Ohhashi, T. Effective permeability of hydrophilic substances through walls of lymph vessels: roles of endothe lial barrier. Am. J. Physiol. Heart Circ. Physiol., 2005, 289(4), H1676-H1682.
57. Patterson, R.M.; Ballard, C.L.; Wasserman, K.; Mayerson, H.S. Capillary permeability to macromolecules. Am. J. Physiol., 1955, 42(4), 432-433.
58. Sundar, S.S.; Ganesan, T.S. Role of lymphangiogenesis in cancer. J. Clin. Oncol., 2007, 25(27), 4298-4307.
59. Oussoren, C.; Storm, G. Role of lymphangiogenesis in cancer. Adv. Drug Deliv. Rev., 2001, 50(2), 143-156.
60. Kim, K.C.; Han, J.H. Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats. J. Microencapsul., 1995, 12(4), 437-446.
61. Oussoren, C.; Storm, G. Role of macrophages in the localisation of liposomes in lymph nodes after subcutaneous administration. Int. J. Pharm., 1999, 183(1), 37-41.
62. Konno, H.; Tadakuma, T.; Kumai, K.; Takahashi, T.; Ishibiki, K.; Abe, O.; Sakaguchi, S. The antitumor effects of adriamycin entrapped in liposomes on lymph node metastases. Jpn. J. Surg., 1990, 20(4), 424-428.
63. Chen, J-H.; Ling, R.; Yao, Q.; Li, Y.; Chen, T.; Wang, Z.; Li, K-Z. Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model. Endocr. Relat. Cancer, 2005, 12(1); 93-100.
64. Nagel, D.; Storm, G.; Kohler, S.; Schlebush, H.; Wagner, U.; Krebs, D. Lymphatic drug targeting with liposomal mitoxantrone for breast cancer- Results of a pilot study. Eur. J. Cancer, 1997, 33, S176.
65. Moghimi, S.M. The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. Biomaterials, 2006, 27(1): 136-144.
66. Grotte, G. Passage of dextran molecules across the blood-lymph barrier. Acta. Chir. Scand. Suppl., 1956, 211(1), 1-84.
67. Takakura, Y.; Mahato, R.I.; Hashida, M. Extravasation of macromolecules. Adv. Drug Deli. Rev., 1998, 34(1), 93-108.
68. Seymour, L.W. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst., 1992, 9(2), 135-187.
69. Bell, D.R.; Watson, P.D.; Renkin, E.M. Exclusion of plasma proteins in interstitium of tissues from the dog hind paw. Am. J. Physiol., 1980, 239(4), H532-H538.
70. Renkin, E.M.; Joyner, W.L; Sloop, C.H.; Watson, P.D. Influence of venous pressure on plasma-lymph transport in the dog's paw: convective and dissipative mechanisms. Microvasc. Res., 1977, 14(2), 191-204.
71. Van Hinsbergh, V.W.; Van Nieuw Amerongen, G.P. Intracellular signalling involved in modulating human endothelial barrier function. J. Anat., 2002, 200(6), 549-560.
72. El-Sayed, M.; Kiani, M.F.; Daimark, M.D.; Hikal, A.H.; Ghandehar, H. Extravasation of poly(amidoamine) (PAMAM) dendrimers across microvascular network endothelium. Pharm. Res., 2001, 18(1), 23-28.
73. Krasnici, S.; Werner, A.; Eichhorn, M.E.; Schmitt-Sody, M.; Pahernik, S.A.; Sauer, B.; Schulze, B.; Teifel, M.; Michaelis, U.; Naujoks, K.; Dellian, M. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int. J. Cancer, 2003, 105(4), 561-567.
74. Wiig, H.; Kolmannskog, O.; Tenstad, O.; Bert, J.L. Effect of charge on interstitial distribution of albumin in rat dermis in vitro. J. Physiol., 2003, 550(2), 505-514.
75. Wiig, H.; Tenstad, O. Interstitial exclusion of positively and negatively charged IgG in rat skin and muscle. Am. J. Physiol. Heart Circ. Physiol., 2001, 280(4), H1505-H1512.
76. Wiig, H.; Gyenge, C.C.; Tenstad, O. The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. J. Physiol., 2005, 567(2), 557-567.
77. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 1986, 46(12 Pt1), 6387-6392.
78. Noguchi, Y.; Wu, J.; Duncan, R.; Strohalm, J.; Ulbrich, K.; Akaike, T.; Maeda, H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res., 1998, 89(3), 307-314.
79. Dreher, M.R.; Liu, W.; Michelich, C.R.; Dewhirst, M.K.; Yuan, F.; Chilkoit, A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst., 2006, 98(5), 335-344.
80. Leu, A.J.; Berk, D.A.; Lympboussaki, A.; Alitalo, K.; Jain, R.K. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res., 2000, 60(16), 4324-4327.
81. Shiah, J.G.; Dvorak, M.; Kopeckova, P.; Sun, Y.; Peterson, C.M.; Kopecek, J. Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice. Eur. J. Cancer, 2001, 37(1), 131-139.
82. Gabizon, A.; Martin, F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs, 1997, 54(suppl 4), 15-21.
83. Symon, Z.; Peyser, A.; Tzemach, D.; Lyass, O.; Sucher, E.; Shezen, E.; Gabizon, A. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer, 1999, 86(1), 72-78.
84. O'Brien, M.E.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D.G.; Tomczak, P.; Ackland, S.P.; Orlandi, F.; Mellars, L.; Tendler, C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol., 2004, 15(3), 440-449.
85. Minshall, R.D.; Malik, A.B. Transport across the endothelium: regulation of endothelial permeability. Handb. Exp. Pharmacol., 2006, 176(pt1), 107-144.
86. Predescu, S.A.; Predescue, D.N.; Malik, A.B. Molecular determinants of endothelial transcytosis and their role in endothelial permeability. Am. J. Physiol. Lung Cell Mol. Physiol., 2007, 293(4), L823-L842.
87. Predescu, D.; Simionescu, M.; Simionescu, N.; Palade, G.E. Binding and transcytosis of glycoalbumin by the microvascular endothelium of the murine myocardium: evidence that glycoalbumin behaves as a bifunctional ligand. J. Cell Biol., 1988, 107(5), 1729-1738.
88. Conner, S.D.; Schmid, S.L. Regulated portals of entry into the cell. Nature, 2003, 422(1), 37-44.
89. Kruth, H.S.; Jones, N.L.; Huang, W.; Zhao,B.; Ishii, I.; Chang, J.; Combs, C.A.; Malide, D.; Zhang, W-Y. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem., 2005, 280(3), 2352-2360.
90. Mousavi, S.A.; Malerod, L.; Berg, T.; Kjeken, R. Clathrin-dependent endocytosis. Biochem. J., 2004, 377(1), 1-16.
91. Brodsky, F.M.; Chen, C-Y.; Knuehl, C.; Towler, M.C.; Wakeham, D.E. Biological basket weaving: formation and function of clathrin-coated vesicles. Annu. Rev. Cell Dev. Biol., 2001, 17(5), 517-68.
92. Leprince, C.; Le Scolan, E.; Meunier, B.; Fraisier, V.; Brandon, N.; De Gunzburg, J.; Camonis, J. Sorting nexin 4 and amphiphysin 2, a new partnership between endocytosis and intracellular trafficking. J. Cell Sci., 2003, 116(10), 1937-1948.
93. Jiang, R-F.; Greener, T.; Barouch, W.; Greene, L. Eisenberg, E. Interaction of auxilin with the molecular chaperone, Hsc70. J. Biol. Chem., 1997, 272(10), 6141-6145.
94. Nabi, I.R.; Le, P.U. Caveolae/raft-dependent endocytosis. J. Cell Biol., 2003, 161(4), 673-677.
95. Razani, B.; Woodman, S.E.; Lisanti, M.P. Caveolae: from cell biology to animal physiology. Pharmacol. Rev., 2002, 54(3), 431-467.
96. Oh, P.; McIntosh, D.P.; Schnitzer, J.E. Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium. J. Cell Biol., 1998, 141(1), 101-114.
97. Minshall, R.D.; Tiruppathi, C.; Vogel, S.M.; Niles, W.D.; Gilchrist, A.; Hamm, H.E.; Malik, A.B. Endothelial cell-surface gp60 activates vesicle formation and trafficking via G(i)-coupled Src kinase signaling pathway. J. Cell Biol., 2000, 150(5), 1057-1070.
98. Schnitzer, J.E.; Oh, P.; Pinney, E.; Allard, J. Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J. Cell. Biol., 1994, 127(5), 1217-1232.
99. Schnitzer, J.E.; Oh, P. Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins. J. Biol. Chem., 1994, 269(8), 6072-6082.
100. Goldstein, J.L.; Brown, M.S.; Anderson, R.G.; Russell, D.W.; Schneider, W.J. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu. Rev. Cell Biol., 1985, 1, 1-39.
101. Oka, Y.; Rozek, L.M.; Czech, M.P. Direct demonstration of rapid insulin-like growth factor II Receptor internalization and recycling in rat adipocytes. Insulin stimulates 125I-insulin-like growth factor II degradation by modulating the IGF-II receptor recycling process. J. Biol. Chem., 1985, 260(16), 9435-9442.
102. Dautry-Varsat, A.; Ciechanover, A.; Lodish, H.F. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc. Natl. Acad. Sci. USA., 1983, 80(8), 2258-2262.
103. Giebing, G.; Tolle, M.; Jurgensen, J.; Eichhorst, J.; Furkert, J.; Beyermann, M.; Neuschafer-Rube, F.; Rosenthal, W.; Zidek, W.; van der Giet, M.; Oksche, A. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circ. Res., 2005, 97(7), 707-715.
104. Ober, R.J.; Martinez, C.; Vaccaro, C.; Zhou, J.; Ward, E.S. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J. Immunol., 2004, 172(4), 2021-2029.
105. McCarthy, K.M.; Yoong, Y.; Simister, N.E. Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: a system to study protein transport across epithelia. J. Cell. Sci., 2000, 113(Pt 7), 1277-1285.
106. Daniels, T.R.; Delgado, T.; Rodriguez, J.A.; Helguera, G.; Penichet, M.L. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol., 2006, 121(2), 159-176.
107. Laske, D.W.; Ilercil, O.; Akbasak, A.; Youle, R.J.; Oldfield, E.H. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J. Neurosurg., 1994, 80(3), 520-526.
108. Laske, D.W.; Youle, R.J.; Oldfield, E.H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med., 1997, 3(12), 1362-1368.
109. Singh, M.; Atwal, H.; Micetich, R. Transferrin directed delivery of adriamycin to human cells. Anticancer Res., 1998, 18(3A), 1423-1427.
110. Lai, B.T.; Gao, J.P.; Lanks, K.W. Mechanism of action and spectrum of cell lines sensitive to a doxorubicin-transferrin conjugate. Cancer Chemother. Pharmacol., 1998, 41(2), 155-160.
111. Hilgenbrink, A.R.; Low, P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci., 2005, 94(10), 2135-2146.
112. Lu, J.Y.; Lowe, D.A.; Kennedy, M.D.; Low, P.S. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J. Drug Target, 1999, 7(1), 43-53.
113. Leamon, C.P.; Reddy, J.A. Folate-targeted chemotherapy. Adv. Drug Deliv. Rev., 2004, 56(8), 1127-1141.
114. Jefferies, W.A.; Brandon, M.R.; Hunt, S.V.; Williams, A.F.; Gatter, K.C.; Mason, D.Y. Transferrin receptor on endothelium of brain capillaries. Nature, 1984, 312(5990), 162-163.
115. Pardridge, W.M. Drug targeting to the brain. Pharm. Res., 2007, 24(9), 1733-1744.
116. Broadwell, R.D.; Baker-Cairns, B.J.; Friden, P.M.; Oliver, C.; Villegas, J.C. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Exp. Neurol., 1996, 142(1), 47-65.
117. Wu, D.; Song, B.W.; Vinters, H.V.; Pardridge, W.M. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J. Drug Target, 2002, 10(3), 239-245.
118. Pardridge, W.M. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug. Chem., 2008, 19(7), 1327-1338.
119. Boado, R.J.; Zhang, Y.; Zhang, Y.; Pardridge, W.M. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol. Bioeng., 2007, 97(6), 1376-1386.
120. Werle, M.; Bernkop-Schnurch, A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids, 2006, 30(3), 351-367.
121. Nauck, M.A.; Holst, J.J.; Willms, B.; Schmiegel, W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp. Clin. Endocrinol. Diabetes, 1997, 105(4), 187-195.
122. Zhu, L.; Tamvakopoulos, C.; Xie, C.; Dragovic, J.; Shen, X.; Fenyk-Melody, J.E.; Schmidt, K.; Bagchi, A.; Griffin, P.R.; Thornberry, N.A.; Sinha Roy, R. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J. Biol. Chem., 2003, 278(25), 22418-22423.
123. Copley, K.; McCowen, K.; Hiles, R.; Nielsen, L.L.; Young, A.; Parkes, D.G. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr. Drug Metab., 2006, 7(3), 367-374.
124. Lahlou, N.; Carel, J.C.; Chaussain, J.L.; Roger, M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J. Pediatr. Endocrinol. Metab., 2000, 13(suppl. 1), 723-737.
125. Rafferty, B.; Coy, D.H.; Poole, S. Pharmacokinetic evaluation of superactive analogues of growth hormone-releasing factor (1-29)-amide. Peptides, 1988, 9(1), 207-209.
126. Green, B.D.; Mooney, M.H.; Gault, V.A.; Irwin, N.; Bailey, C.J.; Harriott, P.; Greer, B.; O'Harte, F.P.; Flatt, P.R. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihypergly-caemic activity. J. Endocrinol., 2004, 180(3), 379-388.
127. Nauck, M.A.; Wollschlager, D.; Werner, J.; Holst, J.J.; Orskov, C.; Creutzfeldt, W.; Willms, B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia, 1996, 39(12), 1546-1553.
128. Lee, S-H.; Lee, S.; Youn, Y.S.; Na, D.H.; Chae, S.Y.; Byun, Y.; Lee, K.C. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug. Chem., 2005, 16(3), 377-382.
129. Claus, T.H.; Pan, C.Q.; Buxton, J.M.; Yang, L.; Reynolds, J.C.; Barucci, N.; Burns, M.; Ortiz, A.A.; Roczniak, S.; Livingston, J.N.; Clairmont, K.B.; Whelan, J.P. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. J. Endocrinol., 2007, 192(2), 371-380.
130. Jain, S.; Hreczuk-Hirst, D.H.; McCormack, B.; Mital, M.; Epenetos, A.; Laing, P.; Gregoriadis, G. Polysialylated insulin: synthesis, characterization and biological activity in vivo. Biochem. Biophys. Acta, 2003, 1622(1), 42-49.
131. Hideshima, T.; Bradner, J.E.; Chauhan, D.; Anderson, K.C. Intracellular protein degradation and its therapeutic implications. Clin. Cancer Res., 2005, 11(24), 8530-8533.
132. Pshezhetsky, A.V.; Ashmarina, M. Lysosomal multienzyme complex: biochemistry, genetics, and molecular pathophysiology. Prog Nucleic Acid Res. Mol. Biol. 2001, 69(1), 81-114.
133. Kisselev, A.F.; Akopian, T.N.; Castillo, V.; Goldberg, A.L. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol. Cell. 1999, 4(3), 395-402.
134. Ciechanover, A. The ubiquitin proteolytic system: from an idea to the patient bed. Proc. Am. Thorac. Soc., 2006, 3(1), 21-31.
135. Seyrantepe, V.; Hinek, A.; Peng, J.; Fedjave, M.; Ernest, S.; Kadota, Y.; Canuel, M.; Itoh, K.; Morales, C.R.; Lavoie, J.; Tremblay, J.; Pshezhetsky, A.V. Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1. Circulation, 2008, 117(15), 1973-1981.
136. Poole, B.; Ohkuma, S. and Warburton, M.J. Protein Turnover and Lysosome Functio; Segal, H.L.; Doyle, D.J. Eds. Academic Press, New York, 1978; pp. 43-58.
137. Haraldsson, B.; Sörensson, J. Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. News Physiol Sci., 2004, 19 (1), 7-10.
138. Deen, W.M.; Lazzara, M.J.; Meyers, B.D. Structural determinants of glomerular permeability. Am. J. Physiol. Renal Physiol., 2001, 281(4), F579-F596.
139. Hansen, C.P.; Goetze, J.P.; Stadil, F.; Rehfeld, J.F. Excretion of progastrin products in human urine. Am. J. Physiol. Gastrointest. Liver Physiol., 1999, 276(4 Pt. 1), G985-G992.
140. Holmes, G.; Galitz, L.; Hu, P.; Lyness, W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br. J. Clin. Pharmacol., 2005, 60(5), 469-476.
141. Azizi, M.; Ezan, E.; Reny, J.L.; Wdzieczak-Bakala, J.; Gerineau, V.; Menard, J. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl- proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans. Hypertension, 1999, 33(3), 879-886.
142. Salhanick, A. I.; Clairmont, K.B.; Buckholz, T.M.; Pellegrino, C.M.; Ha, S.; Lumb, K.J. Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulin-otropic polypeptide. Bioorg. Med. Chem. Lett., 2005, 15(18), 4114-4117.
143. Andersen, S.R.; Lambrecht, L.J.; Swan, S.K.; Culter, D.L.; Radwanski, E. Affrime, M.B.; Garaud, J.J. Disposition of recombinant human interleukin-10 in subjects with various degrees of renal function. J. Clin. Pharmacol., 1999, 39(10), 1015-1020.
144. Kuwabara, T.; Ishikawa, Y.; Kobayashi, H.; Kobayashi, S.; Sugiyama, Y. Renal clearance of a recombinant granulocyte colony-stimulating factor, nartograstim, in rats. Pharm. Res., 1995, 12(10), 1466-1469.
145. Yang, B. B.; Lum, P.K.; Hayashi, M.M.; Roskos, L.K. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J. Pharm. Sci., 2004, 93(5), 1367-1373.
146. Yang, B.B.; Kido, A.; Salfi, M.; Swan, S.; Sullivan, J.T. Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function. J. Clin. Pharmcol., 2008, 48(9), 1025-1031.
147. Ammons, W.S.; Bauer, R.J.; Horwitz, A.H.; Chen, Z.J.; Bautista, E.; Ruan, H.H.; Abramova, M.; Scott, K.R.; Dedrick, R.L. In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. Neoplasia, 2003, 5(2), 146-154.
148. Bauer, R.J.; Gibbons, J.A.; Bell, D.P.; Luo, Z-P.; Young, J.D. Nonlinear pharmacokinetics of recombinant human macrophage colony-stimulating factor (M-CSF) in rats. J. Pharmacol. Exp. Ther., 1994, 268(1), 152-158.
149. Redman, B.G.; Flaherty, L.; Chou, T.H.; Kraut, M.; Martino, S.; Simon, M.; Valdivieso, M.; Groves, E. Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer. J. Immunother., 1992, 12(1), 50-54.
150. Kotto-Kome, A.C.; Fox, S.E.; Lu, W.; Yang, B.B.; Christensen, R.D.; Calhoun, D.A. Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharm. Res., 2004, 50(1), 55-58.
151. Yang, B.B. In Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Cases Studies in Drug Development; Meibohm, B., Ed. Wiley-Vch, Weinheim, Germany, 2006, pp. 373-393.
152. Kato, M.; Kamiyama, H.; Okazaki, A.; Kumaki, K.; Kato, Y.; Sugiyama, Y. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J. Pharmacol. Exp. Ther., 1997, 283(2), 520-527.
153. Jin, F.; Krzyzanski, W. Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS Pharm. Sci., 2004, 6(1), 1-8.
154. Lammerts van Bueren, J.J.; Bleeker, W.K.; Bogh, H.O.; Houtkamp, M.; Schuurman, J.; van de Winkel, J.G.; Parren, P.W. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res., 2006, 66(15), 7630-7638.
155. Tokuda, Y.; Watanabe, T.; Omuro, Y.; Ando, M.; Katusmata, N.; Okumura, A.; Ohta, M.; Fujii, H.; Sasaki, Y.; Niwa, T.; Tajima,T. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neuoverexpressing metastatic breast cancer. Br. J. Cancer., 1999, 81(8), 1419-1425.
156. Austin, C.D.; De Maziere, A.M.; Pisacane, P.I.; van Dijk, S.M.; Eigenbrot, C.; Sliwkowski, M.X.; Klumperman, J.; Scheller, R.H. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell., 2004, 15(12), 5268-5282.
157. Bauer, R.J.; Dedrick, R.L.; White, M.L.; Murray, M.J.; Garovoy, M.R. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J. Pharmacokinet. Biopharm., 1999, 27(4), 397-420.
158. Den Broeder, A.; van de Putte, L.; Rau, R.; Schattenkirchner, M.; Van Riel, P.; sander, O.; Binder, C.; Fenner, H.; Bankmann, Y.; Velagapudi, R.; Kempeni, J.; Kupper, H. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J. Rheumatol., 2002, 29(11), 2288-2298.
159. Centocor Inc. Remicade® (infliximab) Package Insert, 2004.
160. Genetech Inc. XOLAIR® (Omalizumab) Package Insert, 2007.
161. Ashwell, G.; Harford, J. The asialoglycoprotein receptor: properties and modulation by ligand. Annu. Rev. Biochem., 1988, 51, 531-554.
162. Taylor, M.E. Structure and function of the macrophage mannose receptor. Results Prob. Cell Diff., 2001, 33(2), 105-121.
163. Drickamer, K. C-type lectin-like domains. Curr. Opin. Struct. Biol., 1999, 9 (5), 585-590.
164. Lee, S.J.; Evers, S.; Roeder, D.; Parlow, A.F.; Risteli, J.; Risteli, L.; Lee, Y.C.; Feizi, T.; Langen, H.; Nussenzweig, M.C. Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science, 2002, 295(5561), 1898-1901.
165. Stockert, R.J. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol. Rev., 1995, 75(30), 591-609.
166. Camani, C.; Kruithof, E.K. Clearance receptors for tissue-type plasminogen activator. Int. J. Hematol., 1994, 60(2), 97-109.
167. Biessen, E.A.; van Teijlingen, M.; Vietsch, H.; Barrett-Bergshoeff, M.M.; Bijsterbosch, M.K.; Rijken, D.C.; van Berkel, T.J.C.; Kuiper, J. Antagonists of the mannose receptor and the LDL receptorrelated protein dramatically delay the clearance of tissue plasminogen activator. Circulation, 1997, 95(1), 46-52.
168. Liao, W-C.; Beierle, F.A.; Stouffer, B.C.; Dockens, R.A.; Abbud, Z.A.; Tay, L.K.; Knaus, D.M.; Raymond, R.H.; Chew, P.H.; Kostis, J.B. Pharmacokinetics of lanoteplase in healty volunteers. Circulation, 1997, 96(suppl I):I-260-I-261. Abstract.
169. Komoriya, K.; Kato, Y.; Hayashi, Y.; Ohsuye, K.; Nishigaki, R.; Suigiyama, Y. Characterization of the hepatic disposition of lanoteplase, a rationally designed variant of tissue plasminogen activator in rodents. Drug Metab. Dispos., 2007, 35(3), 469-475.
170. Egrie, J.C.; Browne, J.K. Development and characterization of darbepoetin alfa. Oncology (Williston Park), 2002, 16(10 Suppl 11), 13-22.
171. Keck, R.; Nayak, N.; Lerner, L.; Raju, S.; Ma, S.; Schreitmueller, T.; Chamow, S.; Moorhouse, K.; Kotts, C.; Jones, A. Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. Biologics, 2008, 36(1), 49-60.
172. Robinson, M.A.; Charlton, S.T.; Garnier, P.; Wang, X-T.; Davis, S.S.; Perkins, A.C.; Frier, M.; Duncan, R.; Savage, T.J.; Wyatt, D.A.; Watson, S.A.; Davis, B.G. LEAPT: lectin-directed enzyme-activated prodrug therapy. Proc. Natl. Acad. Sci. USA, 2004, 101(40):14527-14532.
173. De Groot, A.S.; Scoot, D.W. Immunogenicity of protein therapeutics. Trends Immunol., 2007, 28(11), 482-490.
174. Casadevall, N.; Nataf, J. Viron, B.; Kolta, A.; Kiladjian, J.J.; Martin-Dupont, P.; Michaud, P.; Papo, T.; Ugo, V.; Teyssandier, I.; Varet, B.; Mayeux, P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med., 2002, 364(7), 469-475.
175. Wadhwa, M.; Bird, C.; Fagerberg, J.; Gaines-Das, R.; Ragnhammar, P.; Mellstedt, H.; Thorpe, R. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin. Exp. Immunol., 1996, 104(2), 351-358.
176. Milella, M.; Antonelli, G.; Santantonio, T.; Currenti, M.; Monno, L.; Mariano, N.; Angarano, G; Dianzani, F.; Pastore, G. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver, 1993, 13(3), 146-150.
177. Baert, F.; Noman, M.; Vermeire, S.; van Assche, G.; D'Haens, G.; Carbone, A.; Rugeerts, P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med., 2003, 348(7), 601-608.
178. Peters, A.; Klose, O.; Hefty, R.; Keck, F.; Kerner, W. The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin. Diabet. Med., 1995, 12(10), 925-930.
179. Roopenian, D.C.; Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol., 2007, 7(9):715-25.
180. Israel, E.J.; Wilsker, D.F.; Hayes, K.C.; Schoenfeld, D.; Simister, N.E. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology, 1996, 89(4), 573-578.
181. Kim, J.; Bronson, C.L.; Wani, M.A.; Oberyszyn, T.M.; Mohanty, S.; Chaudhury,C.; Hayton, W.L.; Robinson, J.M.; Anderson, C.L. Beta 2-microglobulin deficient mice catabolize IgG more rapidly than FcRn- alpha-chain deficient mice. Exp. Biol. Med., 2008, 233(5), 603-609.
182. Wani, M.A.; Haynes, L.D.; Kim, J.; Bronson, C.L.; Chaudhury, C.; Mohanty, S.; Waldmann, T.A.; Robinson, J.M. Anderson, C.L. Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc. Natl. Acad. Sci. USA., 2006, 103(13), 5084-5089.
183. Medesan, C.; Matesoi, D.; Radu, C.; Ghetie, V.; Ward, E.S. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J. Immunol., 1997, 158(5), 2211-2217.
184. Vaughn, D.E.; Milburn, C.M; Penny, D.M.; Martin, W.L.; Johnson, J.L.; Bjorkman, P.J. Identification of critical IgG binding epitopes on the neonatal Fc receptor. J. Mol. Biol., 1997, 274(4), 597-607.
185. Burmeister, W.P.; Huber, A.H.; Bjorkman, P.J. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature, 1994, 372(6504), 379-383.
186. Dall'Acqua, W.F.; Kiener, P.A.; Wu, H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem., 2006, 281(33), 23514-23524.
187. Hinton, P.R.; Johlfs, M.G.; Xiong, J.M.; Hanestad, K.; Ong, K.C.; Bullock, C.; Keller, S.; Tang, M.T.; Tso, J.Y.; Vasquez, M.; Tsuruhita, N. Engineered human IgG antibodies with longer serum halflives in primates. J. Biol. Chem., 2004, 279(8), 6213-6216.
188. Dall'Acqua, W.F.; Woods, R.M.; Ward, E.S.; Palaszynski, S.R.; Patel, N.K.; Brewah, Y.A.; Wu, H.; Kiener, P.A.; Langermann, S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J. Immunol., 2002, 169(9), 5171-5180.
189. Ternant, D.; Paintaud, G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin. Biol. Ther., 2005, 5 (Suppl. 1), S37-S47.
190. Ward, E.S.; Zhou, J.; Ghetie, V.; Ober, R.J. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int. Immunol., 2003, 15(2), 187-195.
191. Borvak, J.; Richardson, J.; Medesan, C.; Antohe, F.; Radu, C.; Simionescu, M.; Ghetie, V.; Ward, E.S. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Intl. Immunol., 1998, 10(9), 1289-1298.
192. Akilesh, S.; Christianson, G.J.; Roopenion, D.C.; Shaw, A.S. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J. Immunol., 2007, 179(7), 4580-4588.
193. Yu, Z.; Lennon, V.A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N. Engl. J. Med., 1999, 340(3), 227-228.
194. Hansen, R.J.; Balthasar, J.P. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood, 2002, 100(6), 2087-2093.
195. Hansen, R.J.; Balthasar, J.P. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb. Haemost., 2002, 88(6), 898-909.
196. Boxenbaum, H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab. Rev., 1984, 15(5-6), 1071-1121.
197. Lave, T.; Dupin, S.; Schmitt, C.; Chou, R.C; Jaeck, D.; Coassolo, P. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J. Pharm. Sci., 1997, 86(5), 584-590.
198. Mordenti, J.; Chen, S.A.; Moore, J.A.; Ferraiolo, B.L.; Green, J.D. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm. Res., 1991, 8(11), 1351-1359.
199. Richter, W.F.; Gallati, H.; Schiller, C.D. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab. Dispos., 1999, 27(1), 21-25.
200. Grene-Lerouge, N.A.; Bazin-Redureau, M.I.; Debray, M.; Scherrmann, J.M. Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. Toxicol. Appl. Pharmacol., 1996, 138(1), 84-89.
201. Bazin-Redureau, M.; Pepin, S.; Hong, G.; Debray, M.; Scherrmann, J.M. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. Toxicol. Appl. Pharmacol., 1998, 150(2), 295-300.
202. Lin, Y.S.; Nguyen, C.; Mendoza, J.L.; Escandon, E.; Fei, D.; Meng, Y.G.; Modi, N.B. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther., 1999, 288(1), 371-378.
203. Mahmood, I. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J. Pharm. Sci., 2004, 93(1), 177-185.
204. Lin, J.H. In Pharmaceutical Profiling in Drug Discovery for Lead Selection; Borchardt, R.T.; Kerns, E.H.; Lipinski, C.A.; Thakker, D.R.; Wang, B. Eds. AAPS Press, Arlington, VA, 2004, pp. 293-325.
205. Baxter, L.T.; Zhu, H.; Mackensen, D.G.; Jain, R.K. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res., 1994, 54(6), 1517-1528.
206. Baxter, L.T.; Zhu, H.; Mackensen, D.G.; Butler, W.F.; Jain, R.K. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res., 1995, 55(20), 4611-4622.